Long-term gene therapy follow-up study
Part of Blood & lymphatic, Cancer clinical trials.
This study follows patients who received gene therapy at Seattle Children's Hospital to check on their health and safety over time. It helps doctors understand how well the treatment works in the long run.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were in a clinical trial for a Seattle Children's gene therapy product.
- You have already received or will receive the gene therapy treatment in that trial.
- You or your parent or guardian have agreed to join this follow-up study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study monitors participants who received a certain type of CAR T-cell therapy for cancer. It helps researchers understand long-term effects and safety.
This study checks your health over time after you previously received gene-modified cell therapy in a Sorrento-sponsored trial. It helps researchers understand long-term safety and outcomes and may lead to better care for future patients.
This study checks how people do over the long run after receiving a personalized, genetically modified CAR T cell treatment. It may help researchers understand long-term safety and outcomes, which can improve future care.
This study is a long-term follow-up for people who already received gene therapy for sickle cell disease in a specific sponsor’s clinical trial. It helps researchers watch for long-term safety and outcomes over time.
This study checks how people do over the long term after receiving CAR-T, an advanced immune treatment. It may help doctors understand long-term safety and benefits, and what to expect after treatment.
This is a follow-up study for people age 18 or older who previously took part in a CAR T-cell gene therapy trial. It helps researchers check your health over time after that treatment and supports long-term safety and outcomes tracking.
Hear when a new CAR T Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.